Reumatoloxía
Servicio
Inmaculada
Jiménez Nácher
Publicacións nas que colabora con Inmaculada Jiménez Nácher (10)
2010
-
Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C
Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 543-547
-
Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial
HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204
-
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring
Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244
-
Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701
Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 8, pp. 1567-1569
2009
-
Differences in lopinavir plasma concentrations comparing Kaletra® film coated tablets and soft gelatine capsules that result in various lipid abnormalities
Drug Metabolism Letters, Vol. 3, Núm. 2, pp. 67-69
-
Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158
2008
-
Association between tipranavir plasma levels and virological response in HIV-infected patients
AIDS Research and Human Retroviruses, Vol. 24, Núm. 3, pp. 389-391
2007
-
Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards
AIDS Research and Human Retroviruses, Vol. 23, Núm. 11, pp. 1374-1376
2003
-
Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir
AIDS Patient Care and STDs, Vol. 17, Núm. 9, pp. 443-445
2001
-
Episodios oportunistas en pacientes infectados por el virus de la inmunodeficiencia humana durante los primeros 6 meses de la terapia antirretroviral de gran actividad
Medicina Clinica, Vol. 117, Núm. 3, pp. 81-84